Skip to main content
Abiomed wins expanded labeling from FDA for 2 heart pumps
5/14/2019

The FDA has approved expanded premarket labeling for Abiomed's Impella 5.0 and Impella LD heart pumps, allowing them to be used for 14 days in patients with cardiogenic shock. The devices were previously approved for this indication for a duration of six days.

Full Story: